AVENUE THERAPEUTICS INC (ATXI) Stock Price, Quote, News and Overview
NASDAQ:ATXI - Nasdaq - US05360L4032 - Common Stock - Currency: USD
ATXI Quote, Performance and Key Statistics
AVENUE THERAPEUTICS INC
NASDAQ:ATXI (1/24/2025, 8:25:57 PM)
After market: 1.79 -0.1 (-5.29%)1.89
+0.05 (+2.72%)
The current stock price of ATXI is 1.89 USD. In the past month the price increased by 5%. In the past year, price decreased by -83.2%.
ATXI Latest News, Press Releases and Analysis
Avenue Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights
- Topline data in Phase 1b/2a clinical trial of AJ201 for spinal and bulbar muscular atrophy anticipated around year-end 2024...
Avenue Therapeutics to Participate in Maxim Group’s 2024 Healthcare Virtual Summit
MIAMI, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused...
Avenue Therapeutics to Participate in Upcoming Investor Conferences
MIAMI, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company...
ATXI Stock Earnings: Avenue Therapeutics Misses EPS for Q2 2024
ATXI stock results show that Avenue Therapeutics missed analyst estimates for earnings per share the second quarter of 2024.
ATXI Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 77.23 | 745.61B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 29.62 | 390.70B | ||
| JNJ | JOHNSON & JOHNSON | 14.7 | 353.49B | ||
| MRK | MERCK & CO. INC. | 16.06 | 241.71B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 18.13 | 214.16B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.4 | 199.87B | ||
| PFE | PFIZER INC | 10.11 | 147.85B | ||
| SNY | SANOFI-ADR | 12.5 | 131.58B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 51 | 121.02B | ||
| ZTS | ZOETIS INC | 29.27 | 76.07B | ||
| GSK | GSK PLC-SPON ADR | 8.34 | 69.92B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 21.65 | 41.18B |
Related stock screener links
About ATXI
Company Profile
Avenue Therapeutics Inc is a US-based company operating in Pharmaceuticals industry. The company is headquartered in Bay Harbor Islands, Florida and currently employs 3 full-time employees. The company went IPO on 2017-06-27. Avenue Therapeutics, Inc. is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases. The firm is developing three assets including AJ201, an asset for spinal and bulbar muscular atrophy; BAER-101, an oral small molecule selective Gamma-aminobutyric acid receptor A alpha 2 & 3 (GABAA α2, α3) receptor positive allosteric modulator for central nervous system (CNS) diseases; and IV tramadol, which is in phase III clinical development for the management of acute postoperative pain in adults in a medically supervised healthcare setting. AJ201 is a pleiotropic small molecule that is designed to modify multiple mechanisms including degradation of the abnormal AR protein and stimulation of Nrf1 and Nrf2, which are involved in protecting cells form oxidative stress which can lead to cell death. Tramadol, a synthetic dual-acting opioid, is a centrally acting analgesic with weak opioid agonist properties.
Company Info
AVENUE THERAPEUTICS INC
1111 Kane Concourse, Suite 301
Bay Harbor Islands FLORIDA 10036 US
CEO: Lucy Lu
Employees: 3
Company Website: https://avenuetx.com/
Investor Relations: http://ir.avenuetx.com/investors/investors-home/default.aspx
Phone: 17816524500
ATXI FAQ
What is the stock price of ATXI?
The current stock price of ATXI is 1.89 USD.
What is the symbol for AVENUE THERAPEUTICS INC stock?
The exchange symbol of AVENUE THERAPEUTICS INC is ATXI and it is listed on the Nasdaq exchange.
On which exchange is ATXI stock listed?
ATXI stock is listed on the Nasdaq exchange.
Is ATXI a good stock to buy?
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for ATXI, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of ATXI.
Does ATXI stock pay dividends?
ATXI does not pay a dividend.
What is the Price/Earnings (PE) ratio of ATXI?
ATXI does not have a PE ratio as the earnings reported over the last twelve months were negative (-19.25).
What is the Short Interest ratio of ATXI stock?
The outstanding short interest for ATXI is 1.52% of its float.
ATXI Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to ATXI. When comparing the yearly performance of all stocks, ATXI is a bad performer in the overall market: 95.93% of all stocks are doing better.
ATXI Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ATXI. No worries on liquidiy or solvency for ATXI as it has an excellent financial health rating, but there are worries on the profitability.
ATXI Financial Highlights
Over the last trailing twelve months ATXI reported a non-GAAP Earnings per Share(EPS) of -19.25. The EPS increased by 83.44% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -360.69% | ||
| ROE | -362.76% | ||
| Debt/Equity | 0 |
ATXI Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to ATXI. The Buy consensus is the average rating of analysts ratings from 8 analysts.